Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Early heart benefits before major weight changes One of the most intriguing aspects of semaglutide’s cardiovascular impact is the timing of these benefits. Recent analysis of extensive clinical ...

At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first 6 months, and for some ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first six months, and for some ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

“Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its potential to improve health in obesity, heart disease and liver diseas ...

Within six months, the drug reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due to heart failure.

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...